{"result": "(\"entity\"<|>GLP-1<|>ORGANIZATION<|>GLP-1 refers to glucagon-like peptide-1, a hormone involved in glucose metabolism and appetite regulation.)\n##\n(\"entity\"<|>DRAUCKER DJ<|>PERSON<|>Drucker DJ is a researcher known for his work on glucagon-like peptides and their clinical applications.)\n##\n(\"entity\"<|>HABENER JF<|>PERSON<|>Habener JF is a researcher who has contributed to the understanding of glucagon-like peptides.)\n##\n(\"entity\"<|>HOLST JJ<|>PERSON<|>Holst JJ is a researcher involved in the discovery and characterization of glucagon-like peptides.)\n##\n(\"entity\"<|>DM2<|>EVENT<|>DM2 refers to Type 2 Diabetes Mellitus, a chronic condition affecting glucose metabolism.)\n##\n(\"relationship\"<|>DRAUCKER DJ<|>GLP-1<|>Drucker DJ has conducted research on GLP-1 and its clinical implications<|>8)\n##\n(\"relationship\"<|>HABENER JF<|>GLP-1<|>Habener JF has contributed to the research on GLP-1 and its effects<|>8)\n##\n(\"relationship\"<|>HOLST JJ<|>GLP-1<|>Holst JJ has been involved in the discovery and characterization of GLP-1<|>8)\n##\n(\"relationship\"<|>DM2<|>GLP-1<|>GLP-1 is relevant in the treatment and management of Type 2 Diabetes Mellitus (DM2)<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: ina tiene una eliminación hepatobiliar, por\n\n\n\n120                                                                                                                                                                                                                                                               121\n---\n                                                                                                                                                                                                                               DIABETES                         2\n\n\n\n     62  ¿Cuál de los siguientes mecanismos no corresponde a los análogos de GLP-1?                                                    64  En relación con los agonistas del receptor de GLP-1 (arGLP-1), señale cuál de las\n         A. Retarda el vaciamiento gástrico.                                                                                               siguientes afirmaciones no es correcta:\n         B. Incrementa la secreción de glucagón.                                                                                           A. El principal mecanismo de acción de los arGLP-1 consiste en la inhibición directa de las\n         C. Aumenta el número de células β en estudios preclínicos.                                                                            neuronas de la proopiomelanocortina en el hipotálamo.\n         D.  Todas son ciertas.                                                                                                            B. Los efectos de GLP-1 sobre el apetito se encuentran mediados en parte por efectos\n                                                                                                                                               directos sobre la saciedad a nivel del sistema nervioso central.\n                                                                                                                                           C. El núcleo del tracto solitario incluye grupos de neuronas con receptores para GLP-1 que\n         COMENTARIO                                                                                                                            interactúan con las áreas hipotalámicas que regulan la ingesta.\n         Uno de los efectos de los análogos de GLP-1 es el retardo del vaciamiento gástrico, más                                           D.  Los efectos de GLP-1 sobre el apetito se encuentran mediados en parte por el retraso del\n         pronunciado con los análogos de acción corta (lo que determina una mayor incidencia de                                                vaciamiento gástrico.\n         náuseas como efecto adverso), aunque también se observa con los de acción prolongada.\n         Las acciones pancreáticas de GLP-1 incluyen la estimulación de la secreción de insulina                                           COMENTARIO\n         de forma dependiente de la glucosa y un efecto supresor sobre la secreción de glucagón,                                           Las terapias basadas en el péptido 1 similar al glucagón (GLP-1) (los agonistas del recep-\n         responsable de la producción endógena de glucosa.                                                                                 tor de GLP-1) afectan al control de la glucosa a través de varios mecanismos, incluido el\n         Los efectos tróficos sobre la célula β han sido demostrados en animales de experimenta-                                           aumento de la secreción de insulina dependiente de la glucosa, ralentización del vaciado\n         ción, pero no se han establecido de forma sólida en humanos.                                                                      gástrico y reducción del glucagón posprandial y la ingesta de alimentos.\n         Referencias:                                                                                                                      El efecto de saciedad del GLP-1 puede involucrar tanto los reflejos enteroentéricos dentro\n         • Drucker DJ, Habener JF, Holst JJ. Discovery, characterization, and clinical development of the glucagon-like peptides.          de las comidas como los mecanismos de señalización central a través de las comidas, que\n           J Clin Invest. 2017;127(12):4217-27.                                                                                            median los cambios en el apetito y promueven la saciedad.\n                                                                                                                                           Referencias:\n     63  Respecto a las incretinas:                                                                                                        • Manual SEEN endocrinología. Disponible en: http://www.seen.es/manualSeen/manual.aspx (acceso 14 de marzo de 2019).\n         A. El GIP disminuye la secreción de somatostatina.\n         B. El GIP enlentece el vaciamiento gástrico.                                                                                  65  Un paciente con DM2 de 10 años de evolución está en tratamiento con insulina\n         C. El GLP-1 disminuye la secreción de glucagón.                                                                                   basal y no controla la glucemia. ¿Qué opción de intensificación del tratamiento no\n         D.  Todas las respuestas anteriores son ciertas.                                                                                  está incluida en las guías de la ADA actuales?\n                                                                                                                                           A. Insulina basal + insulina rápida en la principal comida.\n         COMENTARIO                                                                                                                        B. Una mezcla de insulina antes del desayuno y otra antes de la cena.\n                                                                                                                                           C. Insulina basal más un análogo de GLP-1.\n         El GIP o polipéptido inhibidor gástrico no afecta a la secreción de somatostatina, y tampoco                                      D.  Todas las opciones están incluidas.\n         ejerce acciones sobre el vaciamiento gástrico. El GLP-1 inhibe la secreción de glucagón.\n         Referencias:\n         • Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology. 2002;122:531-44.      COMENTARIO\n                                                                                                                                           Se debe utilizar un enfoque centrado en el paciente para guiar la elección de los agentes\n                                                                                                                                           farmacológicos. Las consideraciones incluyen                  comorbilidades (enfermedad             cardiovascu-\n                                                                                                                                           lar, insuficiencia cardíaca, enfermedad renal), riesgo\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}